Navigation Links
Vigabatrin in Medical News

Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction

- Study Demonstrates Statistically Significant Efficacy vs. Placebo - - Trial Conducted Under Direction of New York University School of Medicine - CORAL GABLES, Fla., Dec. 7 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ), a...

Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results

... license for nine patents in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive di...in more than 30 countries. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" status by the U.S. Food &...

Catalyst to Focus Resources on its Lead Indication for CPP-109; Cocaine Addiction

...from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-r...

Taurine: Key to the visual toxicity of an anti-epileptic drug for children?

... vigabatrin (Sabril), first intention molecule for the treatme...d strategies for limiting it. They have shown that vigabatrin provokes a marked decrease in the blood level in a...validation of an alternative treatment associating vigabatrin and taurine, this will necessitate several years o...

Controversial medication may decrease spasms for infants with epilepsy

...Finland February 02, 2009 The antiepileptic drug vigabatrin (VGB) has been shown to be one of the best treatme...and produces more reliable results in children. vigabatrin treatment began at a mean age of 7.6 months, and t...ents. "Our results may encourage doctors to use vigabatrin to treat infantile spasms as the risk for visual f...

Hope for treating relapse to methamphetamine abuse

...(DOE) Brookhaven National Laboratory suggests that vigabatrin (a.k.a. gamma vinyl-GABA, or GVG) blocks drug-seek...nvironment. Specifically, animals pre-treated with vigabatrin lost interest in spending time in a location where...he research team. "This animal study suggests that vigabatrin could potentially prevent human methamphetamine ad...

Diet may eliminate spasms for infants with epilepsy

...trophy, and visual field constriction. ACTH, though it is effective in 60-70 percent of cases, also costs more than $80,000 for a one-month supply and vigabatrin is not currently available in the U.S. Both drugs have about a 30-40 percent recurrence rate of spasms as well. Other therapies are not yet proven. ...

Catalyst Pharmaceutical Partners, Inc. Set to Join Russell Microcap(R) Index

...from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-r...

Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance

... are undertaking to stem the cycle of drug addiction through treatment with vigabatrin is continuing to garner interest in the market. We were especially pleased ...of any trial conducted so far for cocaine treatment and that treatment with vigabatrin seems especially promising, even for patients that are hardest to treat -- ...

Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results

...ghts to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. This ind...
Vigabatrin in Medical Technology

Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss

CORAL GABLES, Fla., Aug 21 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) today reported that animal data from a new study sponsored by scientists at the U.S. Department of Energy's Brookhaven National Laboratory appears to demonstrate that taking vigabatrin ...

Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction

...ished clinical and non-clinical results evaluating vigabatrin as a treatment for cocaine addiction. Catalyst ex... in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions an.... The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" ...

Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial

...from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-r...

Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction

...from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-r...

Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results

... far for cocaine treatment and that treatment with vigabatrin seems especially promising, even for patients that...bioequivalent to Sabril(R) Tablets, the version of vigabatrin marketed in Europe by Sanofi Aventis. In Decembe...I double-blind, placebo-controlled trial, in which vigabatrin met its primary efficacy endpoint of abstinence du...

Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction

...lyst announced positive initial top-line results from a 103-patient, investigator-initiated Phase II double-blind, placebo- controlled trial, in which vigabatrin met its primary efficacy endpoint of abstinence during the last weeks of treatment for cocaine addiction. Additional results of this study will be rep...

Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's Investigational Drug to Treat Cocaine and Methamphetamine Addiction

...lence study demonstrating that CPP-109 (Catalyst's vigabatrin Tablets) is bioavailable and bioequivalent to Sabril Tablets, the version of vigabatrin marketed in Europe by Sanofi Aventis. These data p... pre-clinical and clinical literature on Sabril. vigabatrin has been marketed over the past decade in more tha...
Vigabatrin in Biological Technology

Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results

...es that operate under the NIH umbrella, for future vigabatrin addiction trials and to provide a portion of the r...domized, Double-Blind, Placebo-Controlled Trial of vigabatrin for the Treatment of Cocaine Dependence in Mexican...nd Eugene M. Laska, Ph.D. The paper suggests that vigabatrin may be effective in the treatment of cocaine addic...

Catalyst Pharmaceutical Partners Receives NASDAQ Deficiency Notice

... license for nine patents in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive di...in more than 30 countries. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" status by the U.S. Food &...

Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results

...any has obtained from Brookhaven National Laboratory an exclusive worldwide license for nine patents in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents p...

Catalyst Pharmaceutical Partners to Present at the Rodman & Renshaw 10th Annual Global Investment Conference

...from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-r...

Catalyst Pharmaceutical Partners, Inc. Announces a $4.5 Million Registered Direct Common Stock Offering

...from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-r...

Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financial Results

...okhaven National Laboratory an exclusive worldwide license for nine patents and four patents pending in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents p...

Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement

...from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-r...
Other Tags
(Date:9/1/2014)... MN (PRWEB) September 01, 2014 In honor of ... on Aug. 22, Animal Emergency & Referral Center of Minnesota (AERC) ... visits a priority for their cats. , Many people don’t take ... too much of a hassle,” but they wouldn’t decide not to ... signs of a cavity. The same goes for pets. Just like ...
(Date:9/1/2014)... Vegas, NV (PRWEB) September 01, 2014 ... entrepreneurs and online marketers that was developed to automate ... has caught the attention of Shane Michaels, prompting an ... established entrepreneur, the daily duty of managing all of ... business can be quite overwhelming,” reports Michaels. “That’s why ...
(Date:9/1/2014)... Pastor Thompson is an ordained minister and previously worked as ... licensed minister through the Church of the Nazarene and has ... Mexico, Colorado and North Dakota. He and his wife Heather ... also has two beautiful daughters, Brianna, 22 and Bethany, 17. ... Bible College, in Colorado Springs and is currently pursuing his ...
(Date:9/1/2014)... New York, US (PRWEB) September 01, 2014 ... a top-line view into Heartbeat Experts’ perspectives ... the Diabetes market. , Download the flash ... stakeholder strategies for any launching Diabetes product:, ... of differentiation within an increasingly crowded market ...
(Date:8/31/2014)... August 31, 2014 The FDA has ... Facts label. If adopted, the proposed changes would include ... of “added sugars” on the label, and a new ... keep “added sugars” off the label. NutriGold fully supports ... make healthier food choices. “After 20 years, it's time ...
Breaking Medicine News(10 mins):Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 2Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 3Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Diabetes Products 2Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 2Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 3Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 4
(Date:9/1/2014)... nucleotidethe basic building block of DNAcould initiate fragile X syndrome, the ... The Journal of Cell Biology . ... gene on the X chromosome called fragile X mental retardation ... 360 men carry a so-called premutation, in which a series of ... is slightly longer than normal. These repeats are prone to even ...
(Date:9/1/2014)... electron microscopy revealed the presence of tiny blob-like structures ... scientists still don,t know what they do even ... to be crucial to the life of a cell, ... treatment., In the Journal of Cell Biology , ... various backgrounds, from biophysics to cell biology, to focus ...
(Date:9/1/2014)... nocturnal animals, bats are perfectly adapted to a life without ... the reflected echoes to measure distance to obstacles or prey. ... echo delays. A study carried out by researchers at Technische ... this map dynamically adapts to external factors. , ... flies in too close to an object, the number of ...
Breaking Biology News(10 mins):A nucleotide change could initiate fragile X syndrome 2Scientists call for investigation of mysterious cloud-like collections in cells 2Zooming in for a safe flight 2
Other Contents